We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bivictrix Therapeutics Plc | BVX | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 10.00 | 00:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 10.00 | 10.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 11/8/2021 14:16 by hedgehog 100 "Development Bank of Wales supports BiVictriX Therapeutics’ IPO on AIMPublished: 02/08/2021 BiVictriX Therapeutics (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience, has announced its intention to list on the AIM market of the London Stock Exchange/ BiVictriX is proposing to raise £7.5 million (before expenses) by way of a placing and subscription of new ordinary shares as part of its initial public offering (IPO). BiVictriX’s pioneering ‘precision&rsq As a component of the IPO, Iain Ross will join the board as Chair, together with experienced non-executive directors Susan Lowther and Drummond Paris. Professor Bob Hawkins, a world-renowned oncologist and biotech innovator completes the board and will add significant scientific support. Existing lead investor, the Development Bank of Wales, will make an additional £500,000 share purchase and remain the largest shareholder of the company. With BiVictriX’s listing on AIM, 33-year-old CEO Tiffany Thorn will become one of the youngest female CEOs of a UK-based publicly listed technology firm. CEO and Founder of BiVictriX, Tiffany Thorn, said: “This is an exciting step for all of us at BiVictriX. This fundraise will allow us to accelerate our growth and expedite the development and delivery of our next-generation, highly selective cancer therapeutics to patients diagnosed with some of the most difficult-to-treat cancers, in urgent need of more effective therapies. We would like to take this opportunity to offer our sincere gratitude and thanks to all of our supportive investors, both old and new, for their help in enabling us to carry out this crucial work.” Initially receiving seed investment in 2016, BiVictriX has been supported over multiple funding rounds by the Development Bank of Wales. Deputy Fund Manager Mike Bakewell said: “We’ve worked with BiVictriX and Tiffany Thorn for five years, investing seed equity finance as well as subsequent follow-on rounds as the company develops its lead therapeutic candidate. We believe in being a long-term partner to our high-growth technology companies. BiVictriX is developing a unique approach that will truly revolutionise treatment of hard-to-fight cancers like AML. We’re delighted to work with Tiffany and the team as they take their next steps with this AIM listing.” Development Bank of Wales Investment Director Rhian Elston said: “Tiffany and BiVictriX are leading the way in important medical research, as well as breaking down boardroom barriers to women in tech. Tiffany is a highly talented CEO and scientist and BiVictriX’s approach has the clear potential to develop next-generation cancer treatments. Having founded the company at 28 years old, just five years later she will now be one of the youngest female CEOs to list on AIM. She is a true trailblazer. As an investor, we’re committed to long-term partnerships – like our relationship with BiVictriX – and providing patient capital to support companies from seed to listing or exit.” BiVictriX will be fifth company the Development Bank of Wales technology venture investments team has supported to list on AIM." P.S. Thanks 40 Fathoms. |
Posted at 11/8/2021 10:37 by hedgehog 100 From BXV's AIM admission document:"EXPECTED TIMETABLE OF PRINCIPAL EVENTS Publication of this Admission Document 5 August 2021 Admission and commencement of dealings in the Enlarged Share Capital on AIM 8.00 a.m. on 11 August 2021 [Wednesday] Fundraise Shares credited to CREST accounts (where applicable) 12 August 2021 Despatch of definitive share certificates (where applicable) by 3 September 2021" IPO investors (at 20p) won't be receiving their shares until tomorrow, and until then it will be difficult for them to sell. Given the large initial premium I would expect some profit-taking (which will increase liquidity). And new share certificates will not be despatched for a few weeks. |
Posted at 11/8/2021 10:03 by hedgehog 100 "BiVictriX Therapeutics moves to a premium on its AIM debutThe company, which raised a gross £7.5mln from the process, is developing a drug technology that potentially offers a revolution in cancer treatment Ian Lyall 08:55 Wed 11 Aug 2021 BiVictriX Therapeutics PLC (LON:BVX) moved to an early 25% premium on its first day of trading on AIM. The company, which raised a gross £7.5mln from the process, is developing a drug technology that potentially offers a revolution in cancer treatment that is highly targeted and avoids hitting healthy cells. The new funds will be used to expand the team and to bankroll preclinical R&D work on BVX001, a new approach to tackling acute myeloid leukaemia. Listed at 20p, the shares were marked 5p higher in the first hour of trade on the London Stock Exchanges giving a market capitalisation of just shy of £20mln. Chief executive Tiffany Thorn told investors: "Today's listing on London's AIM market is a major milestone for BiVictriX. “Our vision is to revolutionise cancer therapy for the most difficult to treat cancers, making curative treatments available to all. “The funds raised will help us to accelerate our growth and expedite the development and delivery of our pioneering, highly selective cancer therapeutics to patients diagnosed with some of the most challenging cancers and supporting patients who are currently in urgent need of more effective medicines.”" |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
